Alternative promotion and suppression of metastasis by JNK2 governed by its phosphorylation

Sike Hu; Xiaoli Dong; Wenjuan Gao; Dwayne Stupack; Yanhua Liu; Rong Xiang; Na Li

doi:10.18632/oncotarget.17507

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Alternative promotion and suppression of metastasis by JNK2 governed by its phosphorylation

Sike Hu, Xiaoli Dong, Wenjuan Gao, Dwayne Stupack, Yanhua Liu, Rong Xiang and Na Li _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:56569-56581. https://doi.org/10.18632/oncotarget.17507

Metrics: PDF 1768 views | HTML 2661 views | ?

Abstract

Sike Hu1, Xiaoli Dong1, Wenjuan Gao1, Dwayne Stupack2, Yanhua Liu1,3, Rong Xiang1,3,4 and Na Li1,3,4

1School of Medicine, Nankai University, Tianjin 300071, China

2Department of Reproductive Medicine, Division of Gynecologic Oncology, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0987, United States

3 Tianjin Key Laboratory of Tumour Microenvironment and Neurovascular Regulation, Tianjin 300071, China

4Collaborative Innovation Center for Biotherapy, Nankai University, Tianjin 300071, China

Correspondence to:

Na Li, email: [email protected]

Rong Xiang, email: [email protected]

Keywords: JNK2, p-JNK2, Fra1, EMT

Received: December 21, 2016 Accepted: March 30, 2017 Published: April 28, 2017

ABSTRACT

Fos-related antigen 1 (Fra1) has been proposed as a gatekeeper of the mesenchymal-epithelial transition to epithelial-mesenchymal transition. Here, we showed that de-phosphorylated JNK2 increased the expression of Fra1 by promoting the expression of c-Jun and Jun-B. Conversely, phosphorylated JNK2 suppressed its expression via enhancing the ubiquitination of c-Jun and Jun-B. These data provided insights into the regulatory mechanism of JNK2 on the expression of Fra1. Our study thus demonstrated that the conversion of JNK2 from its phosphorylation to de-phosphorylation status promoted the switch of breast cancer cells from mesenchymal-epithelial transition to epithelial-mesenchymal transition.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17507

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Alternative promotion and suppression of metastasis by JNK2 governed by its phosphorylation

Abstract